Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H25NO2 |
| Molecular Weight | 311.418 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(OC[C@H]2CN(C)CC[C@@H]2C3=CC=CC=C3)C=C1
InChI
InChIKey=OJSFTALXCYKKFQ-YLJYHZDGSA-N
InChI=1S/C20H25NO2/c1-21-13-12-20(16-6-4-3-5-7-16)17(14-21)15-23-19-10-8-18(22-2)9-11-19/h3-11,17,20H,12-15H2,1-2H3/t17-,20-/m1/s1
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Chronic thromboembolic pulmonary hypertension. | 2010-04 |
|
| Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression. | 2010 |
|
| Optimizing prophylactic treatment of migraine: Subtypes and patient matching. | 2008-10 |
|
| Antidepressant drugs for narcolepsy. | 2008-01-23 |
|
| Reversal of resistance in microorganisms by help of non-antibiotics. | 2007-06 |
|
| Antidepressant drugs for narcolepsy. | 2005-07-20 |
|
| Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumps. | 2004-06-21 |
|
| Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus. | 2003-09 |
|
| Vibrational circular dichroism spectroscopy study of paroxetine and femoxetine precursors. | 2002 |
|
| Enantiomeric enrichment of (+)-(3R,4S)-4-(4-fluorophenyl)-3-hydroxymethyl-1-methylpiperidine by crystallization. | 2001 |
|
| Inhibition of HIV replication by neuroleptic agents and their potential use in HIV infected patients with AIDS related dementia. | 2000-04 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47794
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C010655
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | |||
|
59859-58-4
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | |||
|
CHEMBL94739
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | |||
|
8Y719ZLX8C
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | |||
|
3012003
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | |||
|
m5259
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | Merck Index | ||
|
C80759
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | |||
|
DTXSID70208576
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | |||
|
SUB07530MIG
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | |||
|
Femoxetine
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | |||
|
100000081238
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | |||
|
3220
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY | |||
|
4032
Created by
admin on Wed Apr 02 09:59:23 GMT 2025 , Edited by admin on Wed Apr 02 09:59:23 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)